Literature DB >> 28885678

Understanding urinary toxicity after radiotherapy for prostate cancer: first steps forward.

Tiziana Rancati1, Federica Palorini1, Cesare Cozzarini2, Claudio Fiorino3, Riccardo Valdagni1,4,5.   

Abstract

One of the most relevant achievements of Professor Gianni Bonadonna was the implementation of the methodology of controlled clinical trials in medical oncology. It is valid for all cancer types, oncological disciplines and clinical endpoints, both survival and toxicity. This narrative review reports on the status of the current knowledge of the radiation-induced urinary syndrome after external-beam radiotherapy for prostate cancer. In recent years, the syndrome has been the object of large-scale prospective observational trials specifically devoted to investigating the association of patient and treatment features with acute/late urinary toxicity. The first results of these trials allow initial attempts at predictive modeling, which can serve as a basis for the optimization of patient selection and treatment planning.

Entities:  

Mesh:

Year:  2017        PMID: 28885678     DOI: 10.5301/tj.5000681

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  4 in total

1.  Treatment of genitourinary carcinoma in dogs using nonsteroidal anti-inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study.

Authors:  Benoit Clerc-Renaud; Tracy L Gieger; Susan M LaRue; Michael W Nolan
Journal:  J Vet Intern Med       Date:  2021-02-26       Impact factor: 3.333

2.  Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy.

Authors:  Vickie C Kong; Jennifer Dang; Winnie Li; Inmaculada Navarro; Jerusha Padayachee; Victor Malkov; Jeff Winter; Srinivas Raman; Alejandro Berlin; Charles Catton; Padraig Warde; Peter Chung
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2022-03-02

Review 3.  Pre-clinical Research on Bladder Toxicity After Radiotherapy for Pelvic Cancers: State-of-the Art and Challenges.

Authors:  Stefania Zuppone; Andrea Bresolin; Antonello E Spinelli; Giuseppe Fallara; Roberta Lucianò; Federico Scarfò; Fabio Benigni; Nadia Di Muzio; Claudio Fiorino; Alberto Briganti; Andrea Salonia; Francesco Montorsi; Riccardo Vago; Cesare Cozzarini
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

4.  A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort.

Authors:  Michela Carlotta Massi; Francesca Gasperoni; Francesca Ieva; Anna Maria Paganoni; Paolo Zunino; Andrea Manzoni; Nicola Rares Franco; Liv Veldeman; Piet Ost; Valérie Fonteyne; Christopher J Talbot; Tim Rattay; Adam Webb; Paul R Symonds; Kerstie Johnson; Maarten Lambrecht; Karin Haustermans; Gert De Meerleer; Dirk de Ruysscher; Ben Vanneste; Evert Van Limbergen; Ananya Choudhury; Rebecca M Elliott; Elena Sperk; Carsten Herskind; Marlon R Veldwijk; Barbara Avuzzi; Tommaso Giandini; Riccardo Valdagni; Alessandro Cicchetti; David Azria; Marie-Pierre Farcy Jacquet; Barry S Rosenstein; Richard G Stock; Kayla Collado; Ana Vega; Miguel Elías Aguado-Barrera; Patricia Calvo; Alison M Dunning; Laura Fachal; Sarah L Kerns; Debbie Payne; Jenny Chang-Claude; Petra Seibold; Catharine M L West; Tiziana Rancati
Journal:  Front Oncol       Date:  2020-10-15       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.